盐酸埃克替尼治疗31例晚期鳞状细胞肺癌临床疗效分析

Efficacy of icotinib hydrochloride in the treatment of 31 patients with advanced squamous cell lung carcinoma

目的:本研究旨在探讨盐酸埃克替尼治疗晚期鳞状细胞肺癌的临床疗效及安全性。方法:回顾分析2011年8月1日-2012年8月30日在浙江省肿瘤医院就诊的使用过盐酸埃克替尼的31例鳞状细胞肺癌患者的临床资料,采用Kaplan-Meier曲线、Cox多因素生存分析模型等进行临床疗效分析。结果:客观缓解率(objective response rate,ORR)6.5%(2例),疾病控制率(disease control rate,DCR)38.7%(12例),中位无进展生存期(median progression-free survival,mPFS)为2.1个月,中位总生存期(median overall survival,mOS)为21.8个月。主要的毒性反应为皮疹38.7%,腹泻16.1%,转氨酶升高6.5%,均以I～II度为主,3.2%出现III度皮疹。结论:盐酸埃克替尼治疗晚期鳞状细胞肺癌有一定疗效,毒性反应患者可耐受。

Objective： To evaluate the efficacy and safety of icotinib hydrochloride in the treatment of pa- tients with advanced squamous cell lung carcinoma. Methods： We retrospectively reviewed medical records of 31 patients with advanced squamous cell lung carcinoma receiving ieotinib hydrochloride therapy from August 1, 2011 to August 30, 2012 in Zhejiang Cancer Hospital. The efficacy was analyzed based on the Kaplan-Meier method and Cox proportional-hazards model. Results： The objective response rate （ORR） was 6.5% （2 patients） , the disease control rate （DCR） was 38.7% （12 patients）, the median progression-free survival （mPFS） was 2. 1 months, and the median overall survival （mOS） was 21.8 months. The main toxic reactions were skin rash （38.7%） , di- arrhea （16.1%） , and elevated transaminase level （6.5%） ; most of them were Grade I to Grade II, and 3.2% appeared skin rash with Grade III. Conclusion： Icotinib hydrochloride is effective for treating patients with ad- vanced squamous cell lung carcinoma, and its toxicity can be tolerated.